Oral and GI Mucositis — Part 3: GI Mucositis, Radiation-Induced Mucositis, and HSCT Considerations
Chemotherapy-induced diarrhea management, irinotecan-specific protocols, immune checkpoint inhibitor colitis, head and neck radiation mucositis, pelvic radiation enteritis, chemoradiation, TBI-related mucositis, palifermin in HSCT, and engraftment syndrome.
12. Gastrointestinal Mucositis: Pathophysiology and Grading
12.1 Pathophysiology
Gastrointestinal (GI) mucositis encompasses the spectrum of mucosal injury affecting the esophagus, stomach, small intestine, and colon caused by cytotoxic cancer therapies. The clinical manifestation most frequently encountered is chemotherapy-induced diarrhea (CID), which reflects injury predominantly to the small intestinal and colonic mucosa.1 2
The pathophysiology of GI mucositis follows the same five-phase model as oral mucositis (see Part 1) but with additional organ-specific features:
- Crypt cell destruction: Intestinal stem cells residing in the crypts of Lieberkuhn are highly proliferative and exquisitely sensitive to cytotoxic agents. Crypt cell apoptosis leads to crypt dropout, villous atrophy, and decreased absorptive surface area.
- Loss of brush border enzymes: Disruption of the mature villous epithelium eliminates lactase, sucrase-isomaltase, and other brush border enzymes, producing osmotic and malabsorptive diarrhea.
- Tight junction disruption: Loss of intercellular tight junction integrity (claudins, occludin, ZO-1) increases paracellular permeability, allowing luminal contents and bacterial products to enter the submucosa and systemic circulation.
- Chloride secretion: Pro-inflammatory mediators (prostaglandins, serotonin/5-HT) stimulate active chloride secretion by crypt enterocytes, producing secretory diarrhea.
- Dysmotility: Serotonin released from enterochromaffin cells accelerates intestinal transit and stimulates enteric neural reflexes.
- Microbiome disruption: Chemotherapy-induced dysbiosis (loss of Lactobacillus, Bifidobacterium, and Clostridiales; overgrowth of Enterobacteriaceae and Enterococcus) impairs mucosal recovery and promotes inflammation. The resultant dysbiosis can persist for weeks to months beyond treatment.
- Bacterial translocation: The combination of mucosal barrier disruption and neutropenia creates the conditions for gram-negative and anaerobic bacterial translocation, which is a significant contributor to febrile neutropenia and sepsis.
12.2 Grading of Chemotherapy-Induced Diarrhea
The NCI CTCAE diarrhea grading (see Part 1, Section 2.2) is the standard scale. For clinical management decisions, a practical severity classification is widely used:2 3
| Category | CTCAE Grade | Clinical Features | Management Level |
|---|---|---|---|
| Uncomplicated | 1–2 | <7 stools/day above baseline; no fever, dehydration, cramping, nausea/vomiting, or blood in stool; ECOG PS 0–1 | Outpatient management |
| Complicated | 3–4, or Grade 1–2 with complicating features | >=7 stools/day; OR any grade with: fever >=38.0°C, dehydration, severe cramping/abdominal pain, nausea/vomiting >=Grade 2, blood in stool, neutropenia (ANC <500), ECOG PS >=2, or recent hospitalization | Inpatient evaluation and management |
13. Chemotherapy-Induced Diarrhea: Prevention and Management
13.1 General Principles
- Assess and grade diarrhea at every clinical encounter during and after chemotherapy
- Rule out other causes before attributing diarrhea solely to chemotherapy: Clostridioides difficile infection, other enteric infections, partial bowel obstruction with overflow, medications (antibiotics, proton pump inhibitors, metformin, laxatives), dietary factors, inflammatory bowel disease flare, graft-versus-host disease
- Stool studies (C. difficile toxin, culture, ova and parasites, viral PCR) should be sent for all patients presenting with Grade 2+ diarrhea, especially in the setting of recent antibiotic use or hospitalization
- Address fluid and electrolyte replacement early
13.2 Loperamide Protocol for Chemotherapy-Induced Diarrhea
Loperamide is the first-line pharmacologic agent for uncomplicated CID. The following intensified dosing regimen has been recommended by expert panels:2 3
Initial dosing:
| Step | Instruction |
|---|---|
| 1 | At the onset of diarrhea (or first unformed stool), take loperamide 4 mg PO (initial loading dose) |
| 2 | Then take loperamide 2 mg PO every 2 hours during waking hours |
| 3 | At night: take loperamide 4 mg PO every 4 hours |
| 4 | Continue until diarrhea-free for 12 hours |
| 5 | Maximum duration at high-dose schedule: 48 hours |
If diarrhea resolves within 24 hours: Resume regular diet gradually; monitor for recurrence.
If diarrhea persists beyond 24 hours at high-dose loperamide: Advance to second-line therapy (see below).
If diarrhea persists beyond 48 hours of high-dose loperamide, or recurs after initial resolution: This is classified as loperamide-refractory diarrhea and requires escalation.
Important cautions:
- Loperamide should be discontinued and the patient urgently evaluated if diarrhea becomes bloody, fever develops, or signs of ileus/obstruction appear
- Loperamide is contraindicated in C. difficile colitis and bacterial enterocolitis with systemic toxicity
- Prolonged high-dose loperamide has been associated with rare cardiac events (QT prolongation) at supratherapeutic doses; standard dosing within the 48-hour protocol is considered safe
13.3 Second-Line and Refractory Diarrhea Management
Octreotide
Octreotide, a synthetic somatostatin analog, is recommended for CID that is refractory to loperamide.2 3
| Parameter | Protocol |
|---|---|
| Indication | Loperamide-refractory CID (Grade 2+ persisting >24–48 hours despite adequate loperamide); severe (Grade 3–4) CID from the outset |
| Initial dose | Octreotide 100–150 mcg SC TID (or 25–50 mcg/hour continuous IV infusion) |
| Dose escalation | If no response in 24 hours, increase to 500 mcg SC TID (maximum 2500 mcg/day in some protocols) |
| Duration | Continue until diarrhea resolves; typically 3–5 days |
| Route | Subcutaneous preferred for outpatients; IV for inpatients |
| Mechanism | Reduces intestinal secretion, inhibits serotonin and vasoactive intestinal peptide release, slows intestinal transit, enhances water and electrolyte absorption |
Budesonide
- Oral budesonide 9 mg PO daily (3 mg TID) has shown benefit in some studies of CID and may be considered for refractory cases
- Evidence is limited; not a standard first-line agent for typical cytotoxic CID
- More established role in immune checkpoint inhibitor (ICI)-related colitis (see Section 14)
Tincture of Opium
- Deodorized tincture of opium (DTO, paregoric): 0.6 mL PO every 4 hours (contains 10 mg/mL morphine equivalent)
- Reserved for refractory cases when loperamide and octreotide are insufficient
- Requires careful dose monitoring; potential for sedation and respiratory depression
Supportive Measures
| Measure | Details |
|---|---|
| Fluid replacement | Oral rehydration solution (ORS) for uncomplicated diarrhea; IV normal saline or lactated Ringer’s for dehydration, Grade 3+ diarrhea, or inability to tolerate oral fluids |
| Electrolyte monitoring and replacement | Check and replace potassium, magnesium, bicarbonate; metabolic acidosis may develop with severe diarrhea |
| Dietary modification | BRAT diet (bananas, rice, applesauce, toast) initially; avoid lactose-containing products, high-fiber foods, caffeine, alcohol, fatty/greasy foods; small frequent meals; advance diet as tolerated |
| Skin care | Barrier creams for perianal area; sitz baths; avoid irritating wipes; consider referral to wound/ostomy nurse for severe perineal skin breakdown |
| Dose modification | Consider chemotherapy dose reduction (typically 25–50%) or treatment delay for subsequent cycles if Grade 3–4 CID occurred; specific guidelines vary by regimen — consult protocol or drug-specific prescribing information |
13.4 Agents with Evidence for CID Prevention
| Agent | Setting | Evidence | Recommendation |
|---|---|---|---|
| Loperamide (prophylactic) | General chemotherapy | Not established | Not recommended for routine prophylaxis; may mask early symptoms |
| Oral budesonide | Irinotecan-based regimens | Limited data suggesting reduced Grade 3–4 diarrhea | No recommendation for or against; may be considered in clinical trial setting |
| Probiotics | General chemotherapy | Conflicting evidence; some studies suggest reduced CID with specific Lactobacillus strains | No recommendation for or against; safety concern in severely neutropenic patients (risk of probiotic bacteremia); if used, discontinue when ANC <500/mcL |
| Activated charcoal | Irinotecan | One study showed potential benefit | No recommendation; insufficient evidence |
| Neomycin or oral antibiotics for gut decontamination | General | Not established | Not recommended for CID prevention |
14. Irinotecan-Specific Diarrhea
Irinotecan (CPT-11) produces a unique dual-mechanism diarrhea that requires distinct management approaches for the early and late phases.4
14.1 Early-Onset Diarrhea (Cholinergic Syndrome)
| Feature | Details |
|---|---|
| Onset | During or within 24 hours of irinotecan infusion |
| Mechanism | Irinotecan inhibits acetylcholinesterase, producing a cholinergic excess syndrome |
| Symptoms | Diarrhea (watery, often explosive), abdominal cramping, diaphoresis, salivation, lacrimation, rhinorrhea, miosis, bradycardia |
| Incidence | Approximately 10–15% of patients |
| Treatment | Atropine 0.25–1.0 mg IV or SC at the time of symptoms; may repeat; some protocols use prophylactic atropine before irinotecan infusion in patients with prior cholinergic reactions |
| Prevention | Atropine premedication (0.25–0.5 mg SC) for patients who experienced cholinergic syndrome with prior doses |
| Key distinction | This is NOT mediated by mucosal damage and does not respond to loperamide |
14.2 Late-Onset Diarrhea (Secretory/Mucosal Injury)
| Feature | Details |
|---|---|
| Onset | >24 hours after irinotecan infusion; typically days 3–10 |
| Mechanism | SN-38 (the active metabolite of irinotecan, generated by hepatic carboxylesterase) causes direct mucosal injury and secretory diarrhea. SN-38 is glucuronidated in the liver (SN-38G) and excreted in bile. Beta-glucuronidase produced by intestinal bacteria reconverts SN-38G back to active SN-38 in the intestinal lumen, causing delayed mucosal damage. Additionally, the UGT1A1 enzyme that glucuronidates SN-38 has clinically significant polymorphisms (e.g., UGT1A1*28 — Gilbert syndrome genotype) that affect SN-38 clearance and toxicity risk. |
| Severity | Can be severe (Grade 3–4 in 20–35% of patients); potentially fatal if not managed promptly |
| Treatment | Aggressive loperamide protocol (see Section 13.2); escalate to octreotide if loperamide-refractory; IV hydration; hospitalization for Grade 3+ or complicated diarrhea |
| UGT1A1 testing | Recommended before initiating irinotecan-based therapy. Patients homozygous for UGT1A1*28 (7/7 genotype) are at significantly increased risk of severe neutropenia and diarrhea; dose reduction (typically initial dose reduction of 25–30%) is recommended by prescribing information. Heterozygous (6/7) patients may also have increased risk. |
14.3 Management Algorithm for Irinotecan-Associated Diarrhea
| Timing | Assessment | Intervention |
|---|---|---|
| During or <24 hours after infusion | Cholinergic symptoms? (diarrhea + diaphoresis, cramping, salivation) | Atropine 0.25–1.0 mg IV/SC; hold infusion until symptoms resolve; resume at slower rate if appropriate |
| >24 hours after infusion, uncomplicated | Grade 1–2, no fever, no neutropenia, no dehydration | Loperamide 4 mg then 2 mg every 2 hours for 48 hours; oral fluids; call if worsening or not resolving in 24 hours |
| >24 hours after infusion, complicated | Grade 3–4 or any complicating feature | Hospitalize; IV fluids; octreotide 100–150 mcg SC TID (escalate if needed); antibiotics if febrile and neutropenic; stool studies (C. difficile); chemotherapy dose reduction for subsequent cycles |
| Loperamide-refractory (>48 hours) | Persistent Grade 2+ diarrhea despite 48 hours of high-dose loperamide | Octreotide as above; IV hydration; consider hospitalization; investigate alternative causes |
15. Immune Checkpoint Inhibitor-Associated Colitis
Immune-mediated colitis is a distinct clinical entity from cytotoxic chemotherapy-induced GI mucositis. It results from immune activation, not direct mucosal cytotoxicity, and requires fundamentally different management.5 6
15.1 Key Differentiating Features
| Feature | Cytotoxic CID | ICI-Associated Colitis |
|---|---|---|
| Mechanism | Direct mucosal injury by cytotoxic agent | Immune-mediated inflammation (T-cell activation against GI mucosa) |
| Histopathology | Crypt apoptosis, villous atrophy | Lymphocytic and neutrophilic infiltration; crypt distortion; can resemble inflammatory bowel disease |
| Onset | Days to 1–2 weeks after chemotherapy; predictable timing relative to treatment cycle | Variable; median onset 6–8 weeks after ICI initiation, but can occur at any time including after treatment discontinuation |
| Associated agents | Fluoropyrimidines, irinotecan, taxanes, etc. | Anti-CTLA-4 (ipilimumab) > anti-PD-1/PD-L1 (nivolumab, pembrolizumab, atezolizumab); highest with combination ICI |
| Loperamide response | Usually effective for mild-moderate cases | May provide symptomatic relief but does not treat the underlying immune-mediated process |
| First-line treatment | Loperamide, octreotide | Corticosteroids |
| Endoscopic appearance | Non-specific mucosal edema, erythema | Ulceration, edema, loss of vascular pattern; may mimic ulcerative colitis or Crohn disease |
15.2 Grading and Management of ICI-Associated Colitis
| CTCAE Grade | Clinical Features | Management |
|---|---|---|
| Grade 1 | <4 stools/day above baseline; asymptomatic | Continue ICI with close monitoring; dietary modification; loperamide PRN; stool studies (C. difficile, enteric pathogens) to rule out infectious cause |
| Grade 2 | 4–6 stools/day above baseline; abdominal pain; mucus or blood in stool | Hold ICI; prednisone 0.5–1 mg/kg/day PO; if no improvement in 3 days, treat as Grade 3; stool studies; consider GI consultation and flexible sigmoidoscopy/colonoscopy with biopsies |
| Grade 3 | >=7 stools/day above baseline; severe abdominal pain; peritoneal signs; fever | Permanently discontinue ICI (especially anti-CTLA-4); hospitalize; methylprednisolone 1–2 mg/kg/day IV; NPO if severe; IV fluids; urgent GI consultation; CT abdomen/pelvis to rule out perforation; colonoscopy with biopsies when feasible |
| Grade 4 | Life-threatening; hemodynamic instability; perforation | Permanently discontinue ICI; hospitalize (ICU if needed); methylprednisolone 2 mg/kg/day IV; surgical consultation; NPO; IV fluids |
15.3 Steroid-Refractory ICI Colitis
If no improvement after 3–5 days of high-dose IV corticosteroids:5 6
| Agent | Dose | Notes |
|---|---|---|
| Infliximab | 5 mg/kg IV single dose; may repeat at 2 weeks if needed | Anti-TNF-alpha monoclonal antibody; first-line for steroid-refractory ICI colitis; contraindicated if perforation or sepsis |
| Vedolizumab | 300 mg IV at weeks 0, 2, and 6 | Gut-selective anti-integrin (alpha-4-beta-7); alternative to infliximab; may be preferred if infliximab contraindicated; less systemic immunosuppression |
Corticosteroid taper: Once symptoms improve to Grade 1 or better, taper steroids slowly over at least 4–8 weeks. Rapid taper is associated with symptom recurrence (reported in 30–40% of patients).
ICI rechallenge: Rechallenge with ICI after Grade 3–4 colitis is generally not recommended for anti-CTLA-4 agents. Rechallenge with anti-PD-1/PD-L1 may be cautiously considered after complete resolution in selected patients with careful monitoring, particularly if the original colitis was anti-CTLA-4-mediated and the rechallenge agent is anti-PD-1.
16. Radiation-Induced Mucositis: Head and Neck
16.1 Clinical Features and Timeline
Head and neck radiation-induced oral mucositis is the most common acute toxicity of curative-intent radiation for head and neck cancers. It develops in a predictable temporal pattern:7 8
| Week of RT (2 Gy/fraction) | Cumulative Dose | Expected Findings |
|---|---|---|
| Week 1 (0–10 Gy) | 10 Gy | Usually normal or mild erythema |
| Week 2 (10–20 Gy) | 20 Gy | Erythema (Grade 1); may begin to experience taste changes |
| Week 3 (20–30 Gy) | 30 Gy | Patchy mucositis (Grade 2); focal ulceration; increasing pain; dysgeusia; beginning of xerostomia |
| Week 4–5 (30–50 Gy) | 40–50 Gy | Confluent mucositis (Grade 3); extensive ulceration with pseudomembrane; severe pain requiring opioid analgesia; difficulty eating; significant xerostomia |
| Week 6–7 (50–70 Gy) | 60–70 Gy | Peak severity; confluent mucositis involving all mucosal surfaces in the treatment field; most patients require modified diet or enteral nutrition; opioid-dependent pain |
| 2–4 weeks post-RT | — | Gradual healing begins; mucositis typically resolves 2–6 weeks after completion of radiation |
| 6–8 weeks post-RT | — | Most patients have resolution of acute mucositis; residual xerostomia, dysgeusia, and mucosal sensitivity may persist for months |
16.2 Exacerbating Factors in Head and Neck Radiation
- Concurrent chemotherapy (cisplatin 100 mg/m² every 3 weeks or weekly 40 mg/m²; cetuximab): Increases incidence and severity of Grade 3+ mucositis from approximately 50% (radiation alone) to 70–80% (chemoradiation)8
- Concurrent cetuximab: Increases mucositis and may cause acneiform rash that complicates assessment
- Treatment breaks/interruptions: Prolonging overall treatment time reduces tumor control; mucositis is the most common reason for unplanned treatment breaks, which should be avoided if at all possible
- Tobacco and alcohol use: Irritate mucosa and impair healing
- Xerostomia: Reduced salivary flow concentrates mucosal irritants and impairs the buffering and antimicrobial functions of saliva
16.3 Prevention Strategies Specific to Head and Neck Radiation
| Intervention | Recommendation | Details |
|---|---|---|
| IMRT (intensity-modulated radiation therapy) | Recommended over 3D conformal when feasible | Reduces the volume of normal mucosal tissue receiving high dose; spares salivary glands (mean parotid dose <26 Gy when achievable); reduces but does not eliminate mucositis |
| Photobiomodulation (PBM) | Recommended | See Part 2, Section 5.3 for parameters; apply before or after each radiation fraction |
| Benzydamine rinse | Suggested for moderate-dose RT (<=50 Gy) | See Part 2, Section 5.6 |
| Basic oral care protocol | Recommended | See Part 2, Section 5.5 |
| Amifostine | No recommendation for or against for mucositis prevention in head and neck radiation | Amifostine is an aminothiol cytoprotectant that may reduce xerostomia; evidence for mucositis reduction is inconsistent; significant adverse effects (hypotension, nausea, allergic reactions) limit use; some guideline panels recommend it for xerostomia prevention but not specifically for mucositis |
| Chlorhexidine rinse | Not recommended | No benefit for radiation mucositis; may cause mucosal irritation |
| Sucralfate | Not recommended | Randomized trials showed no benefit; possible harm |
16.4 Management During Head and Neck Radiation
| Domain | Approach |
|---|---|
| Pain management | Stepwise approach per Part 2, Section 7; topical morphine 0.2% rinse or viscous lidocaine for mild-moderate pain; systemic opioids (morphine, hydromorphone) for severe pain; PCA in hospitalized patients; gabapentin as adjuvant for neuropathic component |
| Nutritional support | Early dietitian referral; consider prophylactic PEG in patients expected to develop severe mucositis (bilateral neck radiation, concurrent chemotherapy, T3–T4 oropharyngeal/hypopharyngeal tumors); maintain swallowing exercises |
| Oral hygiene | Continue gentle brushing and bland rinses throughout; avoid alcohol-containing products; treat candidiasis and HSV promptly |
| Xerostomia management | Frequent sips of water; saliva substitutes (carboxymethylcellulose-based sprays); pilocarpine 5 mg PO TID (if no contraindications) for stimulation of residual salivary function; cevimeline 30 mg PO TID as alternative |
| Treatment continuity | Every effort should be made to avoid unplanned treatment breaks due to mucositis; dose modification of concurrent chemotherapy (e.g., cisplatin dose reduction or hold) may be preferable to radiation interruption |
17. Pelvic Radiation: Enteritis and Proctitis
17.1 Pathophysiology
Pelvic radiation for gynecologic, colorectal, prostate, and bladder cancers frequently causes injury to the small bowel and rectum.9
- Acute radiation enteritis: Onset typically during weeks 2–3 of pelvic radiation; manifests as diarrhea, abdominal cramping, nausea, and urgency
- Acute radiation proctitis: Rectal urgency, tenesmus, mucoid or bloody rectal discharge, rectal pain
- Risk factors: total dose >45 Gy to bowel, large field size, concurrent 5-FU or capecitabine, prior abdominal surgery (adhesions fix small bowel in the pelvis), thin body habitus (less peritoneal fat to displace small bowel)
17.2 Prevention
| Strategy | Details |
|---|---|
| IMRT / VMAT | Preferred over 3D conformal for pelvic malignancies; reduces small bowel volume in treatment field |
| Prone positioning with belly board | Allows small bowel to fall away from the pelvic treatment field; reduces small bowel dose |
| Bladder filling protocol | Full bladder displaces small bowel superiorly out of the radiation field |
| Dietary counseling | Low-residue diet during pelvic radiation; avoid lactose, high-fiber foods, caffeine, alcohol, fatty foods |
| Sulfasalazine | Suggested by some guideline panels for prevention of radiation enteritis; 500 mg PO BID during pelvic radiation; evidence is moderate |
| Amifostine (intrarectal) | Not routinely recommended; some evidence for reduced proctitis; limited availability and practical challenges |
| Probiotics | Conflicting evidence; VSL#3 (now Visbiome) has shown benefit in some studies for radiation enteritis prevention; no strong recommendation for or against |
| Sucralfate enemas | Not recommended for prevention of radiation proctitis; randomized trials showed no benefit |
17.3 Management of Acute Pelvic Radiation Enteritis/Proctitis
| Symptom | First-Line | Second-Line | Notes |
|---|---|---|---|
| Diarrhea | Loperamide 4 mg then 2 mg after each loose stool (max 16 mg/day for chronic use) | Diphenoxylate-atropine; octreotide for refractory cases | Follow CID management principles (Section 13) |
| Rectal urgency/tenesmus | Hydrocortisone rectal foam or enema 100 mg nightly | Mesalamine suppositories 1 g nightly | Topical rectal therapy may reduce inflammation |
| Rectal bleeding | Usually self-limited; monitor hemoglobin | Sucralfate enemas (2 g in 20 mL water BID) for symptomatic rectal bleeding — may have role in treatment even though not effective for prevention | Refer to gastroenterology if severe or persistent |
| Abdominal cramping | Antispasmodics (hyoscyamine 0.125 mg SL every 4 hours PRN) | Low-dose TCA (amitriptyline 10–25 mg at bedtime) for chronic pain | Assess for obstruction if severe |
18. Combined Chemoradiation Considerations
Concurrent chemoradiation (CRT) is the standard of care for many locally advanced cancers (head and neck, cervical, rectal, esophageal, lung). CRT significantly increases the incidence and severity of mucositis compared to either modality alone.7 8
18.1 Key Principles for CRT-Related Mucositis
| Principle | Details |
|---|---|
| Expect enhanced toxicity | Grade 3–4 oral mucositis occurs in 60–80% of head and neck CRT patients (vs. 30–50% with radiation alone); Grade 3–4 diarrhea occurs in 15–25% of pelvic CRT patients (vs. 5–10% with radiation alone) |
| Proactive prevention | All evidence-based prevention strategies (PBM, basic oral care, dietary counseling) should be initiated before treatment starts |
| Monitoring intensity | More frequent assessment is needed compared to either modality alone |
| Treatment continuity | Radiation treatment breaks compromise tumor control; chemotherapy dose modification is preferred over radiation interruptions when mucositis is dose-limiting |
| Supportive care planning | Early involvement of pain management, nutrition (dietitian), and dental services; consider prophylactic enteral access for head and neck CRT patients |
| Chemotherapy dose modification | Standard dose reduction protocols: cisplatin may be held or reduced if severe mucositis; 5-FU dose reduced by 25–50% for Grade 3–4 GI toxicity; capecitabine held for Grade 3+ diarrhea until recovery to Grade <=1, then restart at reduced dose |
19. Mucositis in Hematopoietic Stem Cell Transplantation (HSCT)
19.1 Epidemiology and Significance
Oral mucositis is one of the most common and distressing complications of HSCT, occurring in 70–100% of patients receiving myeloablative conditioning and representing the single most common cause of severe pain in the transplant setting.10 11
| Conditioning Type | Oral Mucositis Incidence (Any Grade) | Grade 3–4 Incidence | Median Duration of Grade 3–4 |
|---|---|---|---|
| Myeloablative with TBI | 90–100% | 70–90% | 7–14 days |
| Myeloablative without TBI | 75–95% | 50–75% | 5–10 days |
| High-dose melphalan (autologous) | 85–100% | 60–80% | 5–8 days |
| Reduced-intensity conditioning | 50–75% | 20–40% | 3–5 days |
19.2 TBI-Related Mucositis
Total body irradiation (TBI) at myeloablative doses (typically 12 Gy in 6 fractions over 3 days or 13.2 Gy in 8 fractions over 4 days) causes direct mucosal injury similar to localized radiation therapy but affecting the entire GI tract simultaneously.10
- Onset: Grade 2+ mucositis typically develops by days +3 to +5 post-transplant
- Peak: Days +7 to +12, coinciding with the neutropenic nadir
- Resolution: Generally begins with neutrophil engraftment (day +12 to +21 for allogeneic, day +10 to +14 for autologous HSCT)
- Additional TBI effects: Nausea, vomiting, diarrhea, parotitis (parotid gland swelling within hours of first TBI fraction)
19.3 Prevention Strategies in HSCT
| Intervention | Recommendation | Evidence |
|---|---|---|
| Palifermin | Recommended for TBI-based myeloablative conditioning for autologous HSCT | See Part 2, Section 5.4; pivotal trial showed reduction in Grade 3–4 mucositis from 98% to 63% |
| Palifermin | May be considered for non-TBI myeloablative conditioning and allogeneic HSCT | Evidence less robust; no pivotal trial in these populations; some institutional protocols use it off-label |
| Oral cryotherapy | Recommended for high-dose melphalan conditioning | See Part 2, Section 5.2 |
| Photobiomodulation (PBM) | Recommended | See Part 2, Section 5.3 |
| Basic oral care protocol | Recommended | See Part 2, Section 5.5 |
| HSV prophylaxis | Strongly recommended for seropositive patients | Acyclovir 400 mg PO BID or valacyclovir 500 mg PO BID |
| Antifungal prophylaxis | Strongly recommended | Fluconazole 200–400 mg PO/IV daily from start of conditioning through engraftment |
| Glutamine (oral) | No recommendation for or against | Conflicting evidence; some studies show modest benefit, others do not; not recommended IV |
19.4 Management of HSCT Mucositis
| Domain | Approach |
|---|---|
| Pain management | Mucositis is the primary cause of pain in the HSCT setting; PCA (morphine or hydromorphone) is the standard of care for Grade 3–4 mucositis; transition to oral analgesics as mucositis begins to heal; see Part 2, Section 7 |
| Nutritional support | Parenteral nutrition (PN) is frequently required for Grade 3–4 mucositis when oral/enteral intake is insufficient; nasogastric tubes are poorly tolerated in patients with severe oropharyngeal mucositis; PN is continued until oral intake recovers to >=60% of estimated caloric needs |
| Infection surveillance | Daily oral assessment; fever during mucositis should prompt blood cultures and empiric broad-spectrum antibiotics per febrile neutropenia protocols; viridans group streptococcal bacteremia is strongly associated with mucositis in the HSCT setting |
| Oral care | Continue gentle oral care throughout the nadir; use ultra-soft toothbrush or toothette sponge if platelet count <30,000/mcL or mucositis precludes brushing; bland rinses (saline ± bicarbonate) at least every 2–4 hours |
| Bleeding management | Oral mucosal bleeding from thrombocytopenia: topical tranexamic acid soaked gauze applied with gentle pressure; platelet transfusion per institutional threshold (typically <10,000/mcL, or <20,000/mcL with active bleeding); avoid aggressive debridement of pseudomembranes |
19.5 Engraftment Syndrome
Engraftment syndrome (ES) is a clinical syndrome occurring around the time of neutrophil engraftment (typically day +10 to +16) that can mimic worsening mucositis or new-onset GVHD.12
| Feature | Details |
|---|---|
| Definition | Non-infectious fever (>=38.3°C), erythematous skin rash, and non-cardiogenic pulmonary edema occurring within 96 hours of neutrophil engraftment |
| Incidence | 7–20% of autologous HSCT; less well characterized in allogeneic HSCT |
| Oral manifestations | May cause transient worsening of oral erythema and mucosal edema that can be confused with mucositis flare or GVHD |
| Mechanism | Cytokine release syndrome associated with rapid neutrophil recovery; IL-6, TNF-alpha, and other pro-inflammatory mediator surge |
| Management | Mild: observation; moderate-severe: methylprednisolone 1 mg/kg IV BID for 3 days, then rapid taper; most patients respond quickly to corticosteroids |
| Distinction from GVHD | ES occurs around engraftment (early), is typically self-limited, and responds rapidly to steroids; acute GVHD typically presents later (day +14 to +100) and involves skin, liver, and/or GI tract with a less rapid steroid response |
20. Late Effects and Long-Term Considerations
20.1 Late Radiation Effects on Oral and GI Mucosa
| Late Effect | Onset | Features | Management |
|---|---|---|---|
| Chronic xerostomia | During RT; may be permanent | Reduced salivary flow; increased dental caries risk; difficulty with mastication, speech, swallowing | Pilocarpine 5 mg PO TID; cevimeline 30 mg PO TID; saliva substitutes; meticulous dental care with daily fluoride application; frequent dental follow-up (every 3–4 months) |
| Osteoradionecrosis (ORN) | Months to years post-RT | Non-healing bone exposure in the irradiated mandible or maxilla; may follow dental extraction or spontaneously | Prevention: avoid post-RT extractions if possible; if needed, antibiotic coverage and atraumatic technique; treatment: conservative debridement, hyperbaric oxygen (controversial), pentoxifylline + tocopherol, surgical resection for refractory cases |
| Chronic radiation enteritis/proctitis | Months to years post-RT | Chronic diarrhea, malabsorption, rectal bleeding, stricture, fistula | Symptom management (antidiarrheals, sucralfate enemas for rectal bleeding, dietary modification); endoscopic therapy (argon plasma coagulation for rectal telangiectasias); surgical consultation for stricture/fistula |
| Trismus | Months post-RT | Fibrosis of masticatory muscles; restricted mouth opening | Jaw exercises (TheraBite device); begin during RT as prevention; physical therapy |
| Dysgeusia | During and after RT | Altered or absent taste; usually recovers partially over 3–12 months | Zinc supplementation (220 mg PO BID) may accelerate recovery; limited evidence |
| Mucosal atrophy/fibrosis | Months post-RT | Thin, friable mucosa susceptible to trauma; telangiectasias | Avoid mucosal trauma; gentle oral care; lubricating rinses |
20.2 Survivorship Oral Health
All cancer survivors who received therapy with mucositis risk should have a long-term oral health plan including:13
- Regular dental follow-up: Every 3–6 months (more frequently for irradiated patients)
- Daily fluoride application for head and neck radiation survivors (custom tray with 1.1% neutral NaF gel for 5 minutes daily — lifelong)
- Salivary function monitoring and management of xerostomia
- Avoidance of dental extractions in the irradiated field when possible; consultation with oral medicine or oral surgery specialist when extractions are unavoidable
- Monitoring for secondary malignancy of the oral cavity in irradiated fields
- Nutritional and swallowing rehabilitation as needed
References
Bowen JM, Gibson RJ, Cummins AG, Keefe DMK. “Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage.” Supportive Care in Cancer, 14(7): 713–731, 2006. DOI: 10.1007/s00520-005-0004-7 ↩︎
Benson AB, Ajani JA, Catalano RB, et al. “Recommended guidelines for the treatment of cancer treatment–induced diarrhea.” Journal of Clinical Oncology, 22(14): 2918–2926, 2004. American Society of Clinical Oncology (ASCO). DOI: 10.1200/JCO.2004.04.132 ↩︎ ↩︎ ↩︎ ↩︎
Peterson DE, Boers-Doets CB, Bensadoun RJ, Herrstedt J. “Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines.” Annals of Oncology, 26(suppl 5): v139–v151, 2015. European Society for Medical Oncology (ESMO). DOI: 10.1093/annonc/mdv202 ↩︎ ↩︎ ↩︎
Stein A, Voigt W, Jordan K. “Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management.” Therapeutic Advances in Medical Oncology, 2(1): 51–63, 2010. DOI: 10.1177/1758834009355164 ↩︎
Haanen JBAG, Carbonnel F, Robert C, et al. “Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines.” Annals of Oncology, 28(suppl 4): iv119–iv142, 2017. European Society for Medical Oncology (ESMO). DOI: 10.1093/annonc/mdx225 ↩︎ ↩︎
Brahmer JR, Lacchetti C, Schneider BJ, et al. “Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline.” Journal of Clinical Oncology, 36(17): 1714–1768, 2018. American Society of Clinical Oncology (ASCO). DOI: 10.1200/JCO.2017.77.6385 ↩︎ ↩︎
Trotti A, Bellm LA, Epstein JB, et al. “Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review.” Radiotherapy and Oncology, 66(3): 253–262, 2003. DOI: 10.1016/S0167-8140(02)00404-8 ↩︎ ↩︎
Elting LS, Keefe DM, Sonis ST, et al. “Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy.” Cancer, 113(10): 2704–2713, 2008. DOI: 10.1002/cncr.23898 ↩︎ ↩︎ ↩︎
Hauer-Jensen M, Denham JW, Andreyev HJ. “Radiation enteropathy — pathogenesis, treatment and prevention.” Nature Reviews Gastroenterology and Hepatology, 11(8): 470–479, 2014. DOI: 10.1038/nrgastro.2014.46 ↩︎
Elad S, Cheng KKF, Lalla RV, et al. “MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.” Cancer, 126(19): 4423–4431, 2020. Multinational Association of Supportive Care in Cancer / International Society of Oral Oncology (MASCC/ISOO). DOI: 10.1002/cncr.33100 ↩︎ ↩︎
Spielberger R, Stiff P, Bensinger W, et al. “Palifermin for oral mucositis after intensive therapy for hematologic cancers.” New England Journal of Medicine, 351(25): 2590–2598, 2004. DOI: 10.1056/NEJMoa040125 ↩︎
Spitzer TR. “Engraftment syndrome: double-edged sword of hematopoietic cell transplants.” Bone Marrow Transplantation, 50(4): 469–475, 2015. DOI: 10.1038/bmt.2014.296 ↩︎
Epstein JB, Thariat J, Bensadoun RJ, et al. “Oral complications of cancer and cancer therapy: from cancer treatment to survivorship.” CA: A Cancer Journal for Clinicians, 62(6): 400–422, 2012. DOI: 10.3322/caac.21157 ↩︎